## Clinical Context This patient has an endoscopically confirmed gastric ulcer with a positive rapid urease test, indicating **Helicobacter pylori infection**. The serum gastrin level is normal, making Zollinger-Ellison syndrome unlikely. ## Management Pathway for H. pylori-Positive Ulcer **Key Point:** The standard of care for H. pylori-positive peptic ulcer disease is **eradication therapy**, not acid suppression alone. Triple therapy (PPI + two antibiotics) achieves >90% eradication rates and prevents ulcer recurrence. **High-Yield:** Current guidelines recommend: - **First-line triple therapy:** PPI (omeprazole 20 mg BD) + amoxicillin (1 g BD) + clarithromycin (500 mg BD) for 14 days - Eradication must be confirmed 4 weeks after therapy completion (urea breath test or stool antigen) - Monotherapy with PPI alone does NOT eradicate H. pylori and risks treatment failure ## Why Triple Therapy is Superior | Approach | Eradication Rate | Ulcer Recurrence | Rationale | |----------|------------------|------------------|----------| | PPI monotherapy | <5% | 80–90% | Does not eliminate bacteria; acid suppression only | | Triple therapy (PPI + 2 antibiotics) | >90% | <5% | Bactericidal; prevents relapse and malignant transformation | | Secretin stimulation | N/A | N/A | Only indicated if gastrin >1000 or clinical suspicion of ZES | **Clinical Pearl:** Gastric ulcers (especially antral) are almost always H. pylori-related or NSAID-related. Since this patient denies NSAIDs and urease is positive, eradication is mandatory to prevent complications (perforation, bleeding, gastric cancer). **Warning:** Do NOT rely on PPI monotherapy in H. pylori-positive disease — this is a common exam trap and leads to treatment failure.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.